Overview

Fibromyalgia and Naltrexone: The FINAL Study

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of low dose naltrexone (LDN) on pain in women with fibromyalgia (FM). The study is designed as a parallel randomized (1:1) double blind, placebo-controlled superiority trial. Half of the participants will receive treatment with LDN while the other half will receive treatment with placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Odense University Hospital
Collaborators:
University Hospital Bispebjerg and Frederiksberg
University of Southern Denmark
Treatments:
Naltrexone